Celularity Inc..
CELU.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Celularity Inc. is a biotechnology company focused on the development of cellular medicines and biomaterials. They harness the power of the placenta to develop innovative therapies for cancer, infectious diseases, and degenerative diseases. Their pipeline includes allogeneic, off-the-shelf cell ther...Show More
Better Health for All
50
Celularity's entire product portfolio and pipeline are focused on health improvement, including stem cell therapies for orthopedics, wound care, pain management, and treatments for cancer, infectious diseases, and Crohn's Disease.
1
There is no evidence of products with negative health outcomes. The company holds over 800 issued patents in cell therapy and regenerative medicine.
2
Celularity operates an FDA-registered, accredited GMP facility.
3
Clinical trials are conducted, and a new Florida law requires patient informed consent for investigational therapies, indicating a baseline for ethical conduct.
4
Fair Money & Economic Opportunity
0
No evidence available to assess Celularity Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While CEO compensation for 2024 was reported as $848,959
1
, the necessary median employee compensation for Celularity Inc. was not provided, preventing the calculation of the CEO median pay ratio. Qualitative mentions of high turnover and the use of contractors were noted in employee reviews
2
, but without specific percentages or details on benefits, these could not be scored against the rubric's quantitative thresholds. An FDA warning letter pertained to product regulatory compliance, not labor law or human rights violations.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Celularity Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company's board of directors has determined that all members, except for Dr. Hariri, are independent directors, meeting Nasdaq and SEC rules.
1
This means 9 out of 10 directors are independent, which is 90%. The nominating and corporate governance committee is responsible for developing a code of business conduct and ethics.
2
The audit committee is tasked with establishing procedures for receiving, retaining, and treating complaints regarding financial controls, accounting, or auditing matters.
3
The company received an FDA warning letter on December 1, 2025, for violations related to an unapproved new drug and unlicensed biological product, with prior responses deemed inadequate.
4
The company also reports delinquent Section 16(a) filings by certain directors and officers.
5
Kind to Animals
-40
Celularity Inc. conducts pre-clinical studies on animals to assess product safety, having developed specific animal models for evaluation.
1
The company is listed for animal usage due to this practice.
2
Annually, 15,000–25,000 animals are used in testing, with small year-on-year declines. Celularity has entered a multi-year research collaboration with Regeneron to support research into allogeneic cell therapy candidates, with an initial focus on targeted allogeneic gamma delta CAR T-cell therapy.
3
The company uses human placenta-derived tissues, described as discarded material, as its primary input.
4
No War, No Weapons
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to the 'No War, No Weapons' ethical value.
1
The articles either provided general corporate governance information without specific details on defense-related activities,
2
were irrelevant to the company (Memsic.com article),
3
or explicitly stated that no relevant data was present.
4
Planet-Friendly Business
0
No evidence available to assess Celularity Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles do not contain any specific, concrete evidence or quantitative data points relevant to Celularity Inc.'s performance regarding 'Respect for Cultures & Communities'. Article
1
discusses a business partnership and a new Florida law, while Article
2
is a general company description.
3
Neither provides information on community engagement, cultural impact, or related metrics.
Safe & Smart Tech
0
No evidence available to assess Celularity Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete evidence regarding Celularity Inc.'s performance on 'Zero Waste & Sustainable Products' KPIs was found in the provided articles. The articles either pertained to different companies, were inaccessible, or described the nature of SEC filings without providing relevant data from them.